Arrowhead Pharmaceuticals
ARWR Nasdaq· Biotechnology
Last close · Oct 26, 2026
$58.98
KIRA · Stoqly’s AI analyst, in plain words
- Arrowhead Pharmaceuticals had $829M of revenue in fiscal 2025, up 23,258.2% on the year before. Over five years, revenue changed +56.6% a year on average.
- Its operating margin was 11.9%, up 16,938.9 pts: of every 100 in sales, about 12 is left after running the business.
- Arrowhead Pharmaceuticals lost $1.6M in fiscal 2025.
- Free cash flow was $157M in fiscal 2025, 18.9% of revenue.
- Arrowhead Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 11.7%.
- Arrowhead Pharmaceuticals has $665M more cash than debt.
Market cap
$8.5B
P/E
—
Revenue
$829M
Net income
−$1.6M
Free cash flow
$157M
Operating margin
11.9%
Arrowhead Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+23,258.2%
Yes. Sales grew 23,258.2% last year.
Does it make a profit?
−0.2%
No. It lost money last year.
Does profit turn into cash?
18.9%
Yes. 18.9% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
What Arrowhead Pharmaceuticals does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Nov 25, 2025
- Legal name
- ARROWHEAD PHARMACEUTICALS, INC.
- CIK
- 0000879407
Arrowhead Pharmaceuticals · ARWR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $138M | $243M | $241M | $3.6M | $829M |
| Revenue growth | 57.2% | 75.9% | −1.0% | −98.5% | 23,258.2% |
| Operating margin | −107.8% | −73.4% | −85.2% | −16,927.1% | 11.9% |
| Net income | −$141M | −$176M | −$205M | −$600M | −$1.6M |
| Net margin | −101.9% | −72.4% | −85.3% | −16,882.4% | −0.2% |
| Diluted EPS | −$1.36 | −$1.67 | −$1.92 | −$5.00 | −$0.01 |
| Cash | |||||
| Cash from operations | $171M | −$136M | −$154M | −$463M | $180M |
| Capital expenditure | $23.6M | $52.8M | $177M | $142M | $22.7M |
| Free cash flow | $148M | −$189M | −$331M | −$604M | $157M |
| FCF margin | 106.8% | −77.7% | −137.3% | −17,018.3% | 18.9% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 3.0% | 1.6% | 1.3% | 12.2% | 11.7% |
| Debt and strength | |||||
| Cash and short-term investments | $311M | $108M | $404M | $681M | $919M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $393M | $255M |
| Shareholders' equity | $409M | $399M | $271M | $185M | $466M |
| Net debt / EBITDA | — | — | — | — | −5.5x |
| Current ratio | 2.6x | 2.9x | 4.0x | 6.7x | 4.9x |
| Interest coverage | — | — | −11.2x | −18.6x | 1.1x |
| Returns and quality | |||||
| Return on capital | −71.2% | −69.1% | −167.1% | — | — |
| Return on equity | −32.4% | −43.6% | −61.3% | −262.5% | −0.5% |
| Piotroski F-score | 3 | 4 | 3 | 2 | 5 |
| Altman Z'' | −0.8 | −1.5 | −2.9 | −4.6 | 0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$37.3M
10 insiders
Of sales under plans
45%
$16.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arrowhead Pharmaceuticals · ARWR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | $8.5B | 23,258.2% | 11.9% | 18.9% | — | — | 5 |
| Harmony Biosciences HRMY | $2.2B | 21.5% | 24.0% | 40.1% | 48.9% | 11.9x | 5 |
| Repligen RGEN | — | 16.4% | 7.5% | 12.7% | 2.4% | — | — |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.8x | 5 |
| Halozyme HALO | $15.5B | 37.6% | 33.6% | 46.2% | 19.2% | 37.3x | 5 |
KIRA
At $58.98 a share, the company is worth $8.5B.
Arrowhead Pharmaceuticals grew sales faster than 4 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000879407). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.